Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

What Was Tested

This randomized controlled trial paper looks at Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Assignment was stratified by baseline glycated haemoglobin A1c (HbA1c), metformin use, and body-mass index (BMI).

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

This study is registered with ClinicalTrials.gov, number NCT03131687.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemic Agents and Immunoglobulin Fc Fragments.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 22 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Lancet (London, England)), a journal based in England.

More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.